BPW
VRTX icon

BlueDoor Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

BlueDoor Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$404K Sell
813
-63
-7% -$27.9K 0.17% 111
2026
Q1 		$391K Buy
876
+59
+7% +$27.5K 0.18% 105
2025
Q4 		$370K Buy
+817
New +$352K 0.17% 110

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlueDoor Private Wealth's VRTX Position: Q2 2026 in Review

BlueDoor Private Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 7.2% in Q2 2026, selling an estimated $27.9K and leaving 813 shares worth $404K. The position accounts for 0.17% of the portfolio, ranked #111.

BlueDoor Private Wealth first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • BlueDoor Private Wealth held 813 shares of Vertex Pharmaceuticals worth $404K as of Q2 2026.
  • BlueDoor Private Wealth sold 63 Vertex Pharmaceuticals shares in Q2 2026, an estimated $27.9K.
  • Vertex Pharmaceuticals made up 0.17% of BlueDoor Private Wealth's portfolio in Q2 2026, its #111 holding.
  • BlueDoor Private Wealth first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on BlueDoor Private Wealth's 13F filing for Q2 2026, filed 16 Jul 2026.